EP3299368B1 - Nouveaux dérivés d'amino pyrimidine - Google Patents

Nouveaux dérivés d'amino pyrimidine Download PDF

Info

Publication number
EP3299368B1
EP3299368B1 EP17191467.4A EP17191467A EP3299368B1 EP 3299368 B1 EP3299368 B1 EP 3299368B1 EP 17191467 A EP17191467 A EP 17191467A EP 3299368 B1 EP3299368 B1 EP 3299368B1
Authority
EP
European Patent Office
Prior art keywords
int
mmol
compound
disease
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17191467.4A
Other languages
German (de)
English (en)
Other versions
EP3299368A1 (fr
Inventor
Daniela Angst
François GESSIER
Anna Vulpetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP23161775.4A priority Critical patent/EP4219478A1/fr
Priority to EP20158961.1A priority patent/EP3689865B1/fr
Priority to RS20200550A priority patent/RS60251B1/sr
Priority to PL17191467T priority patent/PL3299368T3/pl
Priority to DK20158961.1T priority patent/DK3689865T3/da
Application filed by Novartis AG filed Critical Novartis AG
Priority to SI201431570T priority patent/SI3299368T1/sl
Publication of EP3299368A1 publication Critical patent/EP3299368A1/fr
Application granted granted Critical
Publication of EP3299368B1 publication Critical patent/EP3299368B1/fr
Priority to HRP20200775TT priority patent/HRP20200775T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention describes new amino pyrimidine derivatives, as defined herein, that are good drug candidates.
  • the compounds of the present invention may generally exhibit a selective inhibition of Bruton's tyrosine kinase (Btk).
  • Btk The essential role of Btk in autoimmune disease is underlined by the observations that Btk-deficient mice are protected in standard preclinical models for rheumatoid arthritis (Jansson & Holmdahl 1993), systemic lupus erythematosus (Steinberg et al. 1982), as well as allergic disease and anaphylaxis (Hata et al. 1998). In addition, many cancers and lymphomas express Btk and appear to be dependent on Btk function (Davis et al. 2010). The role of BTK in diseases including autoimmunity, inflammation and cancer has been recently reviewed (Tan et al. 2013; Rickert 2013). WO2013/083666 discloses substituted 8-fluoro-2H-isoquinolin-1-one / 8-fluoro2H-phthalazin-1-one compounds which inhibit Btk.
  • Inhibition of Btk activity by the compounds of the present invention may therefore be useful in the treatment of a wide range of disorders, particularly Btk-related diseases or disorders.
  • This may include, but is not limited to autoimmune disorders and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus or vasculitic conditions. It may include, but is not limited to allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD) or conditions caused by delayed or immediate type hypersensitivity and anaphylaxis. It may include, but is not limited to acute or chronic transplant rejection or graft versus host disease. It may include, but is not limited to cancers of hematopoietic origin or solid tumors, including chronic myelogenous leukemia, myeloid leukemia, non-Hodgkin lymphoma and other B cell lymphomas.
  • the present invention provides a compound, or a pharmaceutically acceptable salt thereof, as defined herein, for use as a medicament.
  • the present invention provides a compound, or a pharmaceutically acceptable salt thereof, as defined herein,for use in the treatment of a disease or disorder mediated by Btk.
  • the present invention provides a compound , or a pharmaceutically acceptable salt thereof, which is selected from:
  • the invention provides a compound which is N -(3-(6-Amino-5-(2-( N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; or a pharmaceutically acceptable salt thereof.
  • the invention provides a compound which is N-(3-(5-((1-Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; or a pharmaceutically acceptable salt thereof.
  • the invention provides a compound which is (S)-N-(3-(6-Amino-5-(2-(N-methylacrylamido) propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; or a pharmaceutically acceptable salt thereof.
  • salt or “salts” refers to an acid addition or base addition salt of a compound of the invention.
  • Salts include in particular "pharmaceutically acceptable salts”.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention, as defined herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • any chemical formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the chemical formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 Cl, 125 I respectively.
  • the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labeled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g . D 2 O, d 6 -acetone, d 6 -DMSO.
  • co-crystals that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers.
  • co-crystals may be prepared from a compound of the invention, as defined herein, by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution a compound of the invention, as defined herein, with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163 .
  • the invention further provides co-crystals comprising a compound of the invention, as defined herein.
  • the term "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g ., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329 ). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by Btk, or (ii) associated with Btk activity, or (iii) characterized by activity (normal or abnormal) of Btk; or (2) reducing or inhibiting the activity of Btk; or (3) reducing or inhibiting the expression of Btk.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of Btk; or reducing or inhibiting the expression of Btk partially or completely.
  • the term "subject" refers to an animal. Typically, the animal is a mammal. A subject also refers to, for example, primates ( e.g ., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • primates e.g ., humans, male or female
  • the subject is a primate.
  • the subject is a human.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, ( e.g ., stabilization of a discernible symptom), physiologically, ( e.g ., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • a subject is "in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the ( R )-, ( S )- or ( R , S )- configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the ( R )- or ( S )- configuration.
  • Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- ( Z )- or trans- ( E )- form.
  • a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric ( cis or trans ) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g ., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g ., by fractional crystallization of a salt formed with an optically active acid, e.g.
  • Racemic products can also be resolved by chiral chromatography, e.g ., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds of the present invention, as defined herein may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof), as defined herein, with one or more solvent molecules.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention, as defined herein, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc.
  • the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
  • compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with
  • Tablets may be either film coated or enteric coated according to methods known in the art.
  • compositions for oral administration include an effective amount of a compound of the invention, as defined herein, in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets.
  • excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
  • compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
  • compositions for transdermal application include an effective amount of a compound of the invention, as defined herein, with a suitable carrier.
  • Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g. , for delivery by aerosol or the like.
  • topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention, as defined herein, as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers ( e . g ., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention, as defined herein, as an active ingredient will decompose.
  • agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • the compounds of the invention in free form or in salt form, exhibit valuable pharmacological properties, e.g. Btk modulating properties, e.g. as indicated by in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy.
  • Btk modulating properties e.g. as indicated by in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy.
  • Compounds of the invention may be useful in the treatment of an indication selected from: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable; including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjögren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic dermatitis, allergic
  • compounds of the invention may be useful in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
  • autoimmune disorders inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
  • COPD chronic obstructive pulmonary disease
  • compounds of the invention may be useful in the treatment of cancers of haematopoietic origin including but not limited to multiple myeloma; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; anf / or Waldenstroem disease.
  • compounds of the invention may be useful in the treatment of chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, and/or Grave's disease.
  • compounds of the invention may be prepared by an alternative reaction sequence (shown below) comprising the steps of reacting the amino hydroxypyrimidine 1 with the hydroxyl amino-alkyl-derivative 2' in a Mitsunobu reaction to furnish intermediate 3, which intermediate 3 is then reacted via a Suzuki-coupling to yield intermediate 5, which is then deprotected to yield intermediate 6, which is then amidated with an acid or acid chloride to yield the final product 7 as already described in scheme 1.
  • an alternative reaction sequence shown below comprising the steps of reacting the amino hydroxypyrimidine 1 with the hydroxyl amino-alkyl-derivative 2' in a Mitsunobu reaction to furnish intermediate 3, which intermediate 3 is then reacted via a Suzuki-coupling to yield intermediate 5, which is then deprotected to yield intermediate 6, which is then amidated with an acid or acid chloride to yield the final product 7 as already described in scheme 1.
  • Examples and Reference Examples may be prepared by a reaction sequence involving an alkylation of 4-amino-6-chloropyrimidin-5-ol (1) with an alkyl halide (2) using an appropriate base, Suzuki coupling with a boronic ester (4) usind an appropriate palladium catalyst, such as bis(triphenylphosphine)palladium(II) dichloride, deprotection using an appropriate acid, such as TFA or HCl to form intermediate 6, which is reacted with an appropriate acid or acid chloride using an appropriate coupling reagent, such as T3P, and an appropriate base, such as DIPEA, or in the case of an acid chloride using a base, such as DIPEA, to yield compound 7, i.e. a compound of the invention, as shown in Scheme 1:
  • an appropriate palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride
  • Examples and Reference Examples may be prepared by a reaction sequence involving Mitsunobu reaction of 4-amino-6-chloropyrimidin-5-ol with an alcohol of formula 2' using an appropriate azodicarboxylate, such as DIAD, and Smopex-301 or triphenylphosphine; thereupon the reaction sequences of scheme 1 are being carried out, i.e.
  • an appropriate azodicarboxylate such as DIAD, and Smopex-301 or triphenylphosphine
  • Triphenylphosphine (169 mg, 0.64 mmol) was added to the filtrate.
  • the filtrate was concentrated and the residue was purified by flash chromatography (silica;cyclohexane/EtOAc gradient, 5-40%).
  • the residue was triturated with a mixture of diethyl ether and pentane (1:1) and filtered.
  • the filter cake was washed with pentane and dried in vacuum to afford Reference INT 13 as a white solid.
  • MS (ESI): [M+H] + 406.3, rt 1.40 min.
  • INT 18 was prepared according to Scheme 2 following a procedure analogous to INT 10 replacing N -Boc- N -methyl-2-hydroxyethylamine with (S)-2-(Boc-amino)-1-propanol in step 1, and replacing TFA with HCI in step 3 to afford INT 18 as the hydrochloride salt.
  • MS (ESI): [M+H] + 454.3, rt 0.73 min.
  • Reference INT 23 was prepared following a procedure analogous to INT 2 replacing 1-bromo-5-fluoro-2-methyl-3-nitro-benzene with acetic acid 2-bromo-6-(6-cyclopropyl-1-oxo-3,4-dihydro-1 H -isoquinolin-2-yl)-benzyl ester ( WO2010/000633 ).
  • Reference INT 24 was prepared according to Scheme 2 following a procedure analogous to step 1 of Example 6 replacing N -Boc- N -methyl-2-hydroxyethylamine with ( S )- N -Boc-2-(hydroxymethyl)pyrrolidine.
  • Reference INT 24 content 66%, 200 mg, 0.40 mmol
  • DME dimethylethyl ether
  • Reference INT 23 212 mg, 0.44 mmol
  • aqueous sodium carbonate solution (1 M, 1.20 mL, 1.20 mmol
  • the reaction mixture was stirred at 90 °C for 6 hr.
  • Reference INT 26 was prepared according to Scheme 2 following a procedure analogous to step 3 of Example 6 replacing INT 9 with Reference INT 25.
  • UPLC-MS: MS (ESI): [M+H] + 504.4, rt 0.75 min.
  • Reference INT 27 was prepared according to Scheme 2 following a procedure analogous to INT 26 replacing Reference INT 24 with INT 8 in step 3, and purifying the TFA salt over a SPE cartridge (PL-HCO3 MP resin) to afford Reference INT 27 as the free amine in step 4.
  • Reference INT 28 was prepared following a procedure analogous to WO2002/102790 .
  • INT 30 was prepared according to Scheme 2 following a procedure analogous to step 1 of Example 6 replacing N -Boc- N -methyl-2-hydroxyethylamine with Reference INT 29.
  • Reference INT 35 was prepared according to Scheme 2 following a procedure analogous to step 2 of Reference Example 26 replacing Reference INT 28 with (S)-N-Boc-azetidine-2-carboxylic acid. MS (ESI): [M+H] + 188.1.
  • Reference INT 36 was prepared according to Scheme 2 following a procedure analogous to step 1 of Example 6 replacing N -Boc- N -methyl-hydroxyethylamine with Reference INT 35.
  • Examples and Reference Examples may be prepared by a reaction sequence involving deprotection e.g. with a Lewis acid of 4,6-dichloro-5-methoxypyrimidine 8 to yield 4,6-dichloro-5-hydroxyoxy-pyrimidine 9, followed by a Mitsunobu reaction of the pyrimidinol with an alcohol compound 2' using an appropriate azodicarboxylate, such as DIAD, and Smopex-301 or triphenylphosphine to yield intermediate 10, followed by a nucleophilic aromatic substitution e.g. with ammonia in water to yield the aminopyrimidine intermediate 3. There upon intermediate 3 is converted into a final compound of the invention, i.e.
  • Reference INT 38 To a solution of Reference INT 38 (2.53 g, 10.33 mmol) in DMF (25.0 mL) was added iodomethane (3.2 mL, 51.60 mmol) followed by silver(I) oxide (7.18 g, 31.00 mmol). The reaction mixture was stirred at RT over the weekend. The mixture was diluted with EtOAc and filtered through a pad of Celite. The filtrate was washed with brine, aqueous 10% sodium thiosulfate solution and saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried over sodium sulfate, filtered and concentrated to afford crude Reference INT 39 as a colorless oil.
  • Reference INT 43 was prepared according to Scheme 3 following a procedure analogous to step 2 of Example 6 replacing INT 8 with Reference INT 42.
  • UPLC-MS: MS (ESI): [M+H] + 610.5, rt 1.21 min.
  • Reference INT 44 was prepared according to Scheme 3 following a procedure analogous to step 3 of Example 6 replacing INT 9 with Reference INT 43 and purifying the crude by flash chromatography (silica; DCM/(MeOH with 2% aqueous ammonium hydroxide) gradient, 5-65%) to afford Reference INT 44 as the free amine.
  • MS (ESI): [M+H] + 510.3, rt 0.77 min.
  • Reference examples may be prepared by a reaction sequence involving alkylation of 4,6-dichloro-5-hydroxy-pyrimidine 9 with benzyl bromide using an appropriate base, such as potassium carbonate, followed by nucleophilic aromatic substitution with ammonium hydroxide to yield the aminopyrimidine 12, Suzuki coupling with a boronic ester 4 using an appropriate catalyst, such as bis(triphenylphosphine)-palladium(II) dichloride to yield the benzylated intermediate 13. Cleavage of the benzyl group, e.g.
  • Reference INT 37 content 90%, 6.50 g, 35.50 mmol
  • DMF 120 mL
  • benzyl bromide 8.42 mL, 70.90 mmol
  • potassium carbonate 14.70 g, 106.36 mmol
  • the reaction mixture was stirred at 60 °C for 1 hr.
  • the mixture was concentrated.
  • the residue was partitioned between EtOAc and water.
  • the organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated.
  • the residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-10%) to afford Reference INT 45 as a colorless oil.
  • Reference INT 45 To a solution of Reference INT 45 (8.24 g, 32.30 mmol) in 2-propanol (100 mL) was added aqueous 26% ammonium hydroxide solution (93 mL, 614 mmol) in an autoclave. The reaction mixture was stirred at 80 °C for 12 hr. The mixture was concentrated. The residue was partitioned between EtOAc and water. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to afford crude Reference INT 46 as a white solid.
  • MS (ESI): [M+H] + 236.1, rt 0.84 min.
  • Reference INT 47 (1.16 g, 2.38 mmol) in THF (20 mL) was added Pd-C (116 mg). The reaction mixture was hydrogenated at RT and normal pressure for 48 hr. The mixture was diluted with MeOH (10 mL) and filtered over a pad of Celite. The filtrate was concentrated. The residue was suspended in DCM (20 mL) and TFA (0.918 mL, 11.92 mmol) was added. The mixture was stirred at RT for 30 min, then poured into a mixture of saturated aqueous sodium hydrogen carbonate solution and EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated to afford Reference INT 48 as a beige solid.
  • Reference INT 50 11.00 g, 37.24 mmol
  • DCM 100 mL
  • imidazole 4.30 g, 63.16 mmol
  • tert -butylchlorodiphenylsilane 11.0 mL, 42.82 mmol
  • the reaction mixture was stirred at RT for 3 hr.
  • the suspension was filtered over a thin layer of Celite.
  • the filtrate was washed with water and brine, dried over sodium sulfate, filtered and concentrated.
  • the residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-50%) to afford Reference INT 51 as a colorless oil.
  • Reference INT 51 To a solution of Reference INT 51 (5.06 g, 9.48 mmol) in DMF (75 mL) was added sodium cyanide (1.39 g, 28.40 mmol). The reaction mixture was stirred at 100 °C for 3 hr. The mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-25%) to afford Reference INT 52 as a colorless resin.
  • Reference INT 52 (2.95 g, 6.35 mmol) in THF (30 mL) was added TBAF (1.0 M in THF, 7.5 mL, 7.50 mmol). The reaction mixture was stirred at RT for 2.5 hr. The mixture was concentrated and the residue was taken up in EtOAc. The organic phase was washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (silica; cyclohexane/EtOAc gradient, 0-100%) to afford Reference INT 53 as a colorless residue. MS (ESI): [M+H-tBu] + 171.1.
  • Reference INT 54 content 83%, 313 mg, 0.43 mmol
  • DCM DCM
  • TFA 1.0 mL, 12.98 mmol
  • the reaction mixture was stirred at RT for 1.5 hr.
  • the mixture was concentrated.
  • the residue was purified by flash chromatography (silica; DCM/(MeOH with 2% aqueous ammonium hydroxide) gradient, 0-40%) to afford Reference INT 55 as the free amine as a colorless residue.
  • MS (ESI): [M+H] + 505.3, rt 0.75 min.
  • the inhibitory activity of the present compounds, as defined in the Examples and the Reference Examples, against Btk was assessed in a biochemical enzyme assay.
  • Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express.
  • the assay plates were prepared by addition of 50 nl per well of compound solution in 90 % DMSO.
  • kinase reactions were started by stepwise addition of 4.5 ⁇ l per well of peptide/ATP-solution (4 ⁇ M FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 ⁇ M ATP) in kinase buffer (50mM HEPES, pH 7.5, 1mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 ⁇ M sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ⁇ l per well of enzyme solution (6.4nM full-lenght human recombinant BTK) in kinase buffer.
  • peptide/ATP-solution 4 ⁇ M FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 ⁇ M ATP
  • kinase buffer 50mM HEPES, pH 7.5, 1mM DTT,
  • Kinase reactions were incubated at 30°C for 60 minutes and subsequently terminated by addition of 16 ⁇ l per well of stop solution (100 mM HEPES pH 7.5, 5 % DMSO, 0.1 % Caliper coating reagent, 10 mM EDTA, and 0.015 % Brij35).
  • Stop solution 100 mM HEPES pH 7.5, 5 % DMSO, 0.1 % Caliper coating reagent, 10 mM EDTA, and 0.015 % Brij35.
  • Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100 % inhibition) and without inhibitors (0 % inhibition).
  • the inhibitory activity of the present compounds was assessed in the following in vitro B cell activation assay.
  • Whole blood was collected from the abdominal aorta of anaesthetized adult male Lewis rats and was anticoagulated with 100 U/ml sodium heparin. Blood was then diluted to 50 % with high glucose DMEM (Amimed) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamin, 50 mg/ml dextran 40 and 5% FCS (Fetaclone I, Gibco).
  • 190 ⁇ l prediluted blood was mixed in 96 well U-bottomed microtiter plates (Nunc) with 10 ⁇ l of serial dilutions of test compounds in DMSO. Cultures were incubated at 37°C, 5% CO2 for 1 hour, then 30 ⁇ l of rat IL-4 (Beckton-Dickinson, final concentration 5 ng/ml) and goat anti-rat IgM (Serotec, final concentration 15 ug/ml) were added and the cultures were incubated for 24 hours.
  • rat IL-4 Beckton-Dickinson, final concentration 5 ng/ml
  • goat anti-rat IgM Serotec, final concentration 15 ug/ml
  • Activation of B cells was measured by flow cytometry after staining for the B cell subset with PE-Cy5-labeled anti-ratCD45RA (Beckton-Dickinson) and for the activation marker CD86 (PE-labeled anti-rat CD86 (Beckton-Dickinson). All staining procedures were performed at RT for 30 min in the dark in 96-deep well V-bottomed microtiter plates (Corning) with BD Lysing Solution (Beckton-Dickinson).
  • Cytometric data was acquired on a FACScalibur flow cytometer (BD Biosciences) and the subpopulation of lymphocytes were gated according to size and granularity and further analyzed for expression of CD45RA and the activation markers. Data for the inhibition of B cell activation were calculated from the percentage of cells positively stained for activation markers within the CD45RA positive population. Inhibition data were calculated by comparison to control cultures without anti-IgM and IL-4 (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations.
  • compounds of the invention may generally be useful in the treatment of an indication selected from: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable; including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjögren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis,
  • COPD chronic obstructive pulmonary disease
  • the therapy is selected from a disease which may be treated by an antagonist of Bruton's tyrosine kinase.
  • the invention provides a compound of the invention, as defined herein, for use in a method of treating a disease which is treated by the modulation of Btk- comprising administration of a therapeutically acceptable amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, as defined herein.
  • the disease is selected from the afore-mentioned lists.
  • the compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent.
  • the compound of the present invention, as defined herein may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
  • the compounds of the invention, or a pharmaceutically acceptable salt thereof, as defined herein, may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent.
  • the compounds of the invention, as defined herein may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g.
  • rapamycin 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP23841, TAFA-93, biolimus-7 or biolimus-9; an ascomycin having immunosuppressive properties, e.g. ABT-281, ASM981, etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g.
  • WO 02/38561 or WO 03/82859 e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g. N-benzyl-3,4-dihydroxy-benzylidene-cyanoacetamide ⁇ -cyano-(3,4-dihydroxy)-]N-benzylcinnamamide (Tyrphostin AG 490), prodigiosin 25-C (PNU156804), [4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline] (WHI-P131), [4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline] (WHI-P154), [4-(3',5'-dibromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline] WHI-P97, KRX-211
  • mono-citrate also called CP-690,550
  • sphingosine-1-phosphate receptor modulators such as FTY720 (fingolimod), or compounds disclosed in WO 2005/000833
  • immunosuppressive monoclonal antibodies e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands
  • other immunomodulatory compounds e.g.
  • a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g.
  • a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA
  • paclitaxel gemcitabine, cisplatinum, doxorubicin or 5-fluorouracil; or an anti-infectious agent.
  • Further combination partners to a compound of the invention, as defined herein, may be selected from a PI3K inhibitor (e.g. pan, or alpha, beta, gamma, delta selectives), TNF inhibitors, IL1beta inhibitors, IL17 inhibitors, and inhibitors of IL6 or IL receptor.
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of the invention, as defined herein, and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. a compound of the invention, as defined herein, and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.
  • the invention provides a product comprising a compound of the invention, as defined herein, and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of a disease or condition mediated by Btk kinases.
  • Products provided as a combined preparation include a composition comprising the compound of the invention, as defined herein, and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of the invention, as defined herein, and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention, as defined herein, and another therapeutic agent(s).
  • the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, as defined herein.
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • a container, divided bottle, or divided foil packet An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for administration.
  • the compound of the invention, as defined herein, and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention, as defined herein, and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention, as defined herein, and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention, as defined herein, and the other therapeutic agent.
  • physicians e.g. in the case of a kit comprising the compound of the invention, as defined herein, and the other therapeutic agent
  • the invention provides a compound of the invention, as defined herein, for use in treating a disease or condition mediated by Btk kinases, wherein the medicament is prepared for administration with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in treating a disease or condition mediated by Btk , wherein the medicament is administered with a compound of the invention, as defined herein.
  • the invention also provides a compound of the invention, as defined herein, for use in a method of treating a disease or condition mediated by Btk, wherein the compound of the invention, as defined herein, is prepared for administration with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk , wherein the other therapeutic agent is prepared for administration with a compound of the invention, as defined herein.
  • the invention also provides a compound of the invention, as defined herein, for use in a method of treating a disease or condition mediated by Btk , wherein the compound of the invention, as defined herein, is administered with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk, wherein the other therapeutic agent is administered with a compound of the invention, as defined herein.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (11)

  1. Composé, qui est le N-(3-(6-amino-5-(2-(N-méthylacrylamido)éthoxy)pyrimidin-4-yl)-5-fluoro-2-méthylphényl)-4-cyclopropyl-2-fluorobenzamide, ou un sel pharmaceutiquement acceptable de celui-ci.
  2. Composé, qui est le N-(3-(5-((1-acryloylazétidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-méthylphényl)-4-cyclopropyl-2-fluorobenzamide, ou un sel pharmaceutiquement acceptable de celui-ci.
  3. Composé, qui est le (S)-N-(3-(6-amino-5-(2-(N-méthylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-méthylphényl)-4-cyclopropyl-2-fluorobenzamide, ou un sel pharmaceutiquement acceptable de celui-ci.
  4. Composition pharmaceutique, comprenant une quantité thérapeutiquement efficace d'un composé selon l'une quelconque des revendications 1 à 3, et un ou plusieurs véhicules pharmaceutiquement acceptables.
  5. Combinaison comprenant une quantité thérapeutiquement efficace d'un composé selon l'une quelconque des revendications 1 à 3, ou d'un sel pharmaceutiquement acceptable de celui-ci, et un ou plusieurs co-agents thérapeutiquement actifs.
  6. Composé selon l'une quelconque des revendications 1 à 3, ou sel pharmaceutiquement acceptable de celui-ci, pour une utilisation comme médicament.
  7. Composé selon l'une quelconque des revendications 1 à 3, ou sel pharmaceutiquement acceptable de celui-ci, pour une utilisation dans le traitement d'une maladie ou d'un trouble médié(e) par Btk, où la maladie ou le trouble médié(e) par Btk est choisi(e) parmi les troubles auto-immuns, les maladies inflammatoires, les maladies allergiques, les maladies des voies respiratoires, le rejet de greffe, la polyarthrite rhumatoïde, l'arthrite juvénile idiopathique systémique (AJIS), la goutte, le pemphigus vulgaire, le purpura thrombopénique idiopathique, le lupus érythémateux disséminé, la sclérose en plaques, la myasthénie gravis, le syndrome de Sjögren, l'anémie hémolytique auto-immune, les vascularites associées aux anticorps anti-cytoplasme des neutrophiles (ANCA), la cryoglobulinémie, le purpura thrombocytopénique thrombotique, l'urticaire auto-immune chronique, la dermite atopique, la dermite de contact, la rhinite allergique, l'athérosclérose, le diabète de type 1, le diabète de type 2, l'affection abdominale inflammatoire, la rectocolite hémorragique, la maladie de Crohn, la pancréatite, la glomérulonéphrite, le syndrome de Goodpasture, la thyroïdite de Hashimoto, la maladie de Graves, le rejet de greffe médié par les anticorps (AMR), la réaction de greffe contre hôte, le rejet de greffe hyper-aigu, aigu et chronique, médié par les lymphocytes B ; les troubles thromboemboliques, l'infarctus du myocarde, l'angine de poitrine, les accidents vasculaires cérébraux, troubles ischémiques, l'embolie pulmonaire et les cancers d'origine hématopoïétique.
  8. Composé pour une utilisation selon la revendication 7, où ladite maladie ou ledit trouble est choisi(e) parmi les troubles auto-immuns, les maladies inflammatoires, les maladies allergiques, l'asthme, la broncho-pneumopathie chronique obstructive (BPCO), le rejet de greffe, et les cancers d'origine hématopoïétique ou les tumeurs solides.
  9. Composé pour une utilisation selon la revendication 7, où ladite maladie ou ledit trouble médié(e) par Btk est choisi(e) parmi le myélome multiple, la leucémie, la leucémie myéloïde aiguë, la leucémie myéloïde chronique, la leucémie lymphoïde, la leucémie myéloïde, le lymphome non-hodgkinien, les lymphomes, l'érythrémie, la thrombocytémie essentielle, la myélofibrose avec métaplasie myéloïde et la maladie de Waldenström.
  10. Composé pour une utilisation selon la revendication 7, où ladite maladie ou ledit trouble est choisi(e) parmi l'urticaire auto-immune chronique, la dermite atopique, la dermite de contact, la rhinite allergique, l'athérosclérose, le diabète de type 1, le diabète de type 2, l'affection abdominale inflammatoire, la rectocolite hémorragique, la maladie de Crohn, la pancréatite, la glomérulonéphrite, le syndrome de Goodpasture, la thyroïdite de Hashimoto, et la maladie de Graves.
  11. Composé pour une utilisation selon la revendication 7, où ladite maladie ou ledit trouble est l'urticaire auto-immune chronique.
EP17191467.4A 2013-11-29 2014-11-28 Nouveaux dérivés d'amino pyrimidine Active EP3299368B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP20158961.1A EP3689865B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'amino pyrimidine
RS20200550A RS60251B1 (sr) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
PL17191467T PL3299368T3 (pl) 2013-11-29 2014-11-28 Nowe pochodne aminopirymidyny
DK20158961.1T DK3689865T3 (en) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater
EP23161775.4A EP4219478A1 (fr) 2013-11-29 2014-11-28 Méthode de preparation de dérivés d'amino pyrimidine
SI201431570T SI3299368T1 (sl) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine
EP14821285.5A EP3074386B1 (fr) 2013-11-29 2014-11-28 Nouveaux derivés d'amino pyrimidines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP14821285.5A Division EP3074386B1 (fr) 2013-11-29 2014-11-28 Nouveaux derivés d'amino pyrimidines

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP23161775.4A Division EP4219478A1 (fr) 2013-11-29 2014-11-28 Méthode de preparation de dérivés d'amino pyrimidine
EP20158961.1A Division EP3689865B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'amino pyrimidine

Publications (2)

Publication Number Publication Date
EP3299368A1 EP3299368A1 (fr) 2018-03-28
EP3299368B1 true EP3299368B1 (fr) 2020-02-26

Family

ID=49674216

Family Applications (4)

Application Number Title Priority Date Filing Date
EP17191467.4A Active EP3299368B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'amino pyrimidine
EP23161775.4A Pending EP4219478A1 (fr) 2013-11-29 2014-11-28 Méthode de preparation de dérivés d'amino pyrimidine
EP14821285.5A Active EP3074386B1 (fr) 2013-11-29 2014-11-28 Nouveaux derivés d'amino pyrimidines
EP20158961.1A Active EP3689865B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'amino pyrimidine

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP23161775.4A Pending EP4219478A1 (fr) 2013-11-29 2014-11-28 Méthode de preparation de dérivés d'amino pyrimidine
EP14821285.5A Active EP3074386B1 (fr) 2013-11-29 2014-11-28 Nouveaux derivés d'amino pyrimidines
EP20158961.1A Active EP3689865B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'amino pyrimidine

Country Status (43)

Country Link
US (6) US9512084B2 (fr)
EP (4) EP3299368B1 (fr)
JP (2) JP6342495B2 (fr)
KR (2) KR102421388B1 (fr)
CN (2) CN110172056B (fr)
AP (1) AP2016009158A0 (fr)
AR (1) AR098549A1 (fr)
AU (1) AU2014356069B2 (fr)
BR (1) BR112016010397B1 (fr)
CA (1) CA2926908C (fr)
CL (1) CL2016001055A1 (fr)
CR (1) CR20160244A (fr)
CU (1) CU24384B1 (fr)
CY (3) CY1119705T1 (fr)
DK (3) DK3074386T3 (fr)
EA (1) EA031218B1 (fr)
EC (1) ECSP16054826A (fr)
ES (3) ES2947770T3 (fr)
FI (1) FI3689865T3 (fr)
HK (2) HK1223368A1 (fr)
HR (3) HRP20230585T1 (fr)
HU (3) HUE049794T2 (fr)
IL (1) IL244943B (fr)
JO (1) JO3314B1 (fr)
LT (3) LT3074386T (fr)
MA (1) MA39055B1 (fr)
MX (1) MX367911B (fr)
MY (2) MY191381A (fr)
NO (1) NO3074386T3 (fr)
NZ (1) NZ718835A (fr)
PE (1) PE20160869A1 (fr)
PH (1) PH12016500791B1 (fr)
PL (3) PL3689865T3 (fr)
PT (3) PT3074386T (fr)
RS (3) RS56657B1 (fr)
SI (3) SI3299368T1 (fr)
SV (1) SV2016005206A (fr)
TN (1) TN2016000128A1 (fr)
TW (1) TWI652261B (fr)
UA (1) UA117256C2 (fr)
UY (1) UY35858A (fr)
WO (1) WO2015079417A1 (fr)
ZA (1) ZA201602275B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014576A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Traitement du cancer à l'aide du récepteur antigénique chimérique anti-cd33
EP3193915A1 (fr) 2014-07-21 2017-07-26 Novartis AG Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
EP4205749A1 (fr) 2014-07-31 2023-07-05 Novartis AG Cellules contenant un récepteur d'antigène chimérique optimisé en sous-ensemble
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
RU2724999C2 (ru) 2014-08-19 2020-06-29 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
WO2016044605A1 (fr) 2014-09-17 2016-03-24 Beatty, Gregory Ciblage de cellules cytotoxiques avec des récepteurs chimériques pour l'immunothérapie adoptive
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016057705A1 (fr) 2014-10-08 2016-04-14 Novartis Ag Biomarqueurs prédictifs de la réactivité thérapeutique à une thérapie par récepteurs antigéniques chimères et leurs utilisations
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
DK3280729T3 (da) 2015-04-08 2022-07-25 Novartis Ag Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle
WO2017019896A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
MA44140A (fr) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
CA3031542A1 (fr) 2016-07-20 2018-01-25 University Of Utah Research Foundation Lymphocytes car-t cd229 et leurs procedes d'utilisation
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
JP7227131B2 (ja) 2016-12-03 2023-02-21 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ－ｔ細胞の投薬を決定するための方法
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
BR112019025403A2 (pt) 2017-06-02 2020-08-18 Juno Therapeutics Inc artigos de fabricação e métodos para tratamento usando terapia celular adotiva
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
WO2019089969A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
TW201932482A (zh) 2017-11-01 2019-08-16 美商奇諾治療有限公司 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
WO2019109053A1 (fr) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Procédés de dosage et de modulation de cellules génétiquement modifiées
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
EP3788369A1 (fr) 2018-05-01 2021-03-10 Novartis Ag Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TW202016139A (zh) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
SG11202103873VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
US20220008465A1 (en) 2018-11-16 2022-01-13 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
PE20212198A1 (es) 2019-01-29 2021-11-16 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
WO2020234780A1 (fr) 2019-05-23 2020-11-26 Novartis Ag Méthodes de traitement de l'asthme au moyen d'un inhibiteur de la tyrosine kinase de bruton
KR20220012280A (ko) 2019-05-23 2022-02-03 노파르티스 아게 Btk 저해제의 결정질 형태
JP7568651B2 (ja) 2019-05-23 2024-10-16 ノバルティス アーゲー ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
JP2023508394A (ja) * 2019-12-23 2023-03-02 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
WO2021207689A2 (fr) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Méthodes et utilisations associées à une thérapie cellulaire modifiée à l'aide d'un récepteur antigénique chimérique ciblant un antigène de maturation des lymphocytes b
CA3185469A1 (fr) 2020-08-14 2022-02-17 Novartis Ag Derives de spiropiperidinyle substitues par heteroaryle et leurs utilisations pharmaceutiques
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
WO2022162513A1 (fr) 2021-01-26 2022-08-04 Novartis Ag Composition pharmaceutique
WO2022212893A1 (fr) 2021-04-02 2022-10-06 Biogen Ma Inc. Méthodes de traitement combiné de la sclérose en plaques
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
KR20240122488A (ko) 2021-12-14 2024-08-12 노파르티스 아게 Lou064를 사용한 치료 방법
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (fr) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024069507A1 (fr) 2022-09-30 2024-04-04 Novartis Ag Procédés et intermédiaires de synthèse pour la production de remibrutinib
US20240226298A1 (en) 2022-12-13 2024-07-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
NZ535616A (en) 2000-11-07 2006-03-31 Novartis Ag Indolymaleimide derivatives as protein kinase c inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
EP2322201A3 (fr) 2002-10-29 2011-07-27 Genentech, Inc. Les compositions et les methodes pour le traitement de maladies liées immunisées
PL376844A1 (pl) 2002-12-09 2006-01-09 The Board Of Regents Of The University Of Texas System Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3)
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1473039A1 (fr) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
CN100465173C (zh) 2004-01-12 2009-03-04 西托匹亚研究有限公司 选择性激酶抑制剂
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EP2201840B1 (fr) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de Bruton
SI2134374T1 (sl) 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev
ES2554615T3 (es) 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
CN102083819B (zh) 2008-07-02 2014-07-09 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的新型苯基吡嗪酮
EP2307025B1 (fr) 2008-07-16 2017-09-20 Pharmacyclics LLC Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (fr) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibiteurs de la tyrosien kinase de bruton
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2539343B1 (fr) * 2010-02-26 2015-12-30 Evotec International GmbH Thiénopyrimidines contenant un groupe alkyle substitué pour des compositions pharmaceutiques
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN103889962B (zh) 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
DK2718270T3 (da) 2011-06-10 2022-08-01 Merck Patent Gmbh Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet
EP2726077A4 (fr) 2011-06-28 2014-12-10 Pharmacyclics Inc Procédés et compositions visant à inhiber la résorption osseuse
AU2012282229B2 (en) 2011-07-08 2015-05-07 Novartis Ag Novel pyrrolo pyrimidine derivatives
EP3778896A1 (fr) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
MX361772B (es) 2011-10-19 2018-12-17 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
WO2013083666A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
WO2013157021A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales de ceux-ci
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
US9133134B2 (en) 2012-05-16 2015-09-15 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2013299557B2 (en) 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
WO2014055928A2 (fr) 2012-10-04 2014-04-10 University Of Utah Research Foundation Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
ES2947770T3 (es) 2023-08-18
LT3689865T (lt) 2023-07-10
HK1252317A1 (zh) 2019-05-24
DK3074386T3 (en) 2018-01-22
AR098549A1 (es) 2016-06-01
UY35858A (es) 2015-06-30
DK3299368T3 (da) 2020-05-25
CU20160078A7 (es) 2016-09-30
US20160235746A1 (en) 2016-08-18
PT3689865T (pt) 2023-06-16
ECSP16054826A (es) 2017-10-31
HUE037588T2 (hu) 2018-09-28
CA2926908C (fr) 2021-10-26
CN110172056B (zh) 2022-04-19
JP6667573B2 (ja) 2020-03-18
IL244943A0 (en) 2016-05-31
KR102380539B1 (ko) 2022-03-29
HRP20171999T1 (hr) 2018-02-09
LT3074386T (lt) 2017-12-27
JP6342495B2 (ja) 2018-06-13
UA117256C2 (uk) 2018-07-10
BR112016010397A8 (pt) 2020-04-22
PL3074386T3 (pl) 2018-03-30
CA2926908A1 (fr) 2015-06-04
HRP20230585T1 (hr) 2023-09-01
TW201609666A (zh) 2016-03-16
LT3299368T (lt) 2020-05-25
TN2016000128A1 (en) 2017-10-06
RS60251B1 (sr) 2020-06-30
PL3689865T3 (pl) 2023-07-31
US11180460B2 (en) 2021-11-23
SI3689865T1 (sl) 2023-07-31
AP2016009158A0 (en) 2016-04-30
CN105683181B (zh) 2019-04-23
MX2016006908A (es) 2016-08-17
SI3074386T1 (en) 2018-02-28
US20200010426A1 (en) 2020-01-09
EP3074386B1 (fr) 2017-10-11
KR102421388B1 (ko) 2022-07-18
CL2016001055A1 (es) 2016-10-28
HUE049794T2 (hu) 2020-10-28
PL3299368T3 (pl) 2020-08-10
HUE062248T2 (hu) 2023-10-28
MA39055A1 (fr) 2018-02-28
PT3074386T (pt) 2017-11-15
MX367911B (es) 2019-09-11
NO3074386T3 (fr) 2018-03-10
BR112016010397B1 (pt) 2023-04-11
EA031218B1 (ru) 2018-12-28
CN110172056A (zh) 2019-08-27
KR20220044370A (ko) 2022-04-07
CU24384B1 (es) 2019-03-04
DK3689865T3 (en) 2023-06-19
US9512084B2 (en) 2016-12-06
PH12016500791A1 (en) 2016-06-13
NZ718835A (en) 2021-12-24
SI3299368T1 (sl) 2020-07-31
EP3689865A1 (fr) 2020-08-05
JO3314B1 (ar) 2019-03-13
US10457647B2 (en) 2019-10-29
US20220041561A1 (en) 2022-02-10
WO2015079417A1 (fr) 2015-06-04
US20180251432A1 (en) 2018-09-06
EP3299368A1 (fr) 2018-03-28
FI3689865T3 (fi) 2023-06-12
CY1122924T1 (el) 2021-10-29
CN105683181A (zh) 2016-06-15
US11673868B2 (en) 2023-06-13
PH12016500791B1 (en) 2016-06-13
MY191381A (en) 2022-06-22
TWI652261B (zh) 2019-03-01
ES2655527T3 (es) 2018-02-20
MA39055B1 (fr) 2018-10-31
CY1119705T1 (el) 2018-06-27
ZA201602275B (en) 2017-08-30
JP2018141005A (ja) 2018-09-13
ES2791525T3 (es) 2020-11-04
RS56657B1 (sr) 2018-03-30
AU2014356069A1 (en) 2016-05-05
CR20160244A (es) 2016-07-29
HRP20200775T1 (hr) 2020-07-24
EP3074386A1 (fr) 2016-10-05
EP4219478A1 (fr) 2023-08-02
EA201691125A1 (ru) 2016-09-30
HK1223368A1 (zh) 2017-07-28
CY1126056T1 (el) 2023-11-15
PT3299368T (pt) 2020-05-28
SV2016005206A (es) 2016-11-21
US20230312483A1 (en) 2023-10-05
EP3689865B1 (fr) 2023-03-29
IL244943B (en) 2020-04-30
JP2016538313A (ja) 2016-12-08
MY179059A (en) 2020-10-26
PE20160869A1 (es) 2016-09-08
KR20160088877A (ko) 2016-07-26
AU2014356069B2 (en) 2017-06-15
RS64275B1 (sr) 2023-07-31
US20150152068A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
US11673868B2 (en) Amino pyrimidine derivatives
EP2729466B1 (fr) Nouveaux dérivés de pyrrolopyrimidine
JP6404332B2 (ja) 新規な、ＮＩＫ阻害剤としての３−（１Ｈ−ピラゾール−４−イル）−１Ｈ−ピロロ［２，３−ｃ］ピリジン誘導体
CA3003820A1 (fr) Nouveaux derives de pyrazolo-pyrimidine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3074386

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180928

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190110

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252317

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 403/12 20060101AFI20190731BHEP

Ipc: A61K 31/506 20060101ALI20190731BHEP

Ipc: A61P 35/02 20060101ALI20190731BHEP

Ipc: C07D 401/12 20060101ALI20190731BHEP

Ipc: C07D 405/12 20060101ALI20190731BHEP

Ipc: C07D 401/14 20060101ALI20190731BHEP

Ipc: C07D 239/47 20060101ALI20190731BHEP

Ipc: A61P 29/00 20060101ALI20190731BHEP

Ipc: A61K 31/505 20060101ALI20190731BHEP

Ipc: C07D 401/10 20060101ALI20190731BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190920

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 3074386

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1237496

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014061742

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20200775T

Country of ref document: HR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200520

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3299368

Country of ref document: PT

Date of ref document: 20200528

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20200520

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E019145

Country of ref document: EE

Effective date: 20200512

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20200226

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200401433

Country of ref document: GR

Effective date: 20200716

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20200775

Country of ref document: HR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 34245

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E049794

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2791525

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20201104

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014061742

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200775

Country of ref document: HR

Payment date: 20201112

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20201127

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200775

Country of ref document: HR

Payment date: 20211126

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200775

Country of ref document: HR

Payment date: 20221122

Year of fee payment: 9

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1237496

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200226

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230514

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231026

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200775

Country of ref document: HR

Payment date: 20231026

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20231113

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231024

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231026

Year of fee payment: 10

Ref country code: GB

Payment date: 20231019

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20231027

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231212

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231107

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231124

Year of fee payment: 10

Ref country code: SI

Payment date: 20231025

Year of fee payment: 10

Ref country code: SE

Payment date: 20231026

Year of fee payment: 10

Ref country code: RS

Payment date: 20231106

Year of fee payment: 10

Ref country code: RO

Payment date: 20231027

Year of fee payment: 10

Ref country code: PT

Payment date: 20231115

Year of fee payment: 10

Ref country code: MT

Payment date: 20231117

Year of fee payment: 10

Ref country code: LV

Payment date: 20231019

Year of fee payment: 10

Ref country code: LT

Payment date: 20231116

Year of fee payment: 10

Ref country code: IT

Payment date: 20231026

Year of fee payment: 10

Ref country code: IE

Payment date: 20231123

Year of fee payment: 10

Ref country code: HU

Payment date: 20231106

Year of fee payment: 10

Ref country code: HR

Payment date: 20231026

Year of fee payment: 10

Ref country code: FR

Payment date: 20231024

Year of fee payment: 10

Ref country code: FI

Payment date: 20231116

Year of fee payment: 10

Ref country code: EE

Payment date: 20231023

Year of fee payment: 10

Ref country code: DK

Payment date: 20231116

Year of fee payment: 10

Ref country code: DE

Payment date: 20231017

Year of fee payment: 10

Ref country code: CZ

Payment date: 20231115

Year of fee payment: 10

Ref country code: CY

Payment date: 20231023

Year of fee payment: 10

Ref country code: CH

Payment date: 20231201

Year of fee payment: 10

Ref country code: BG

Payment date: 20231101

Year of fee payment: 10

Ref country code: AT

Payment date: 20231025

Year of fee payment: 10

Ref country code: NO

Payment date: 20231108

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231020

Year of fee payment: 10

Ref country code: BE

Payment date: 20231026

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20231023

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20231121

Year of fee payment: 10